Erin Murphy, DO
Critical Care Medicine · Santa Maria, CANPI 1972995835
Payments from drug & device makers
Across 128 payments — averaging $31.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$918
- AstraZeneca$767
- Vantive US Healthcare LLC$497
- Regeneron Healthcare Solutions, Inc.$393
- Verona Pharma, Inc.$258
- Baxter Healthcare$171
- plus $967 from 14 others
What the payments were for
- Food & beverage$3,74494%
- Education$2015%
- Gifts$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 45 | $918 |
| AstraZeneca | 16 | $767 |
| Vantive US Healthcare LLC | 7 | $497 |
| Regeneron Healthcare Solutions, Inc. | 11 | $393 |
| Verona Pharma, Inc. | 11 | $258 |
| Baxter Healthcare | 5 | $171 |
| Merck | 2 | $146 |
| Asahi Intecc USA, Inc. | 1 | $122 |
| Electromed, Inc. | 6 | $122 |
| Insmed, Inc. | 5 | $116 |
| Actelion Pharmaceuticals US, Inc. | 2 | $94 |
| Mylan Specialty L.p. | 5 | $91 |
| Boehringer Ingelheim | 3 | $77 |
| United Therapeutics Corporation | 2 | $43 |
| Johnson & Johnson | 1 | $37 |
| Medtronic | 2 | $33 |
| Stryker | 1 | $32 |
| Abiomed | 1 | $25 |
| Si-bone, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - PD$396
- TEZSPIRE$249
- NUCALA$248
- TRELEGY ELLIPTA$124
- Asahi Peripheral Vascular Wires$122
- WINREVAIR$112
How this compares
$3,970 in reported general payments places this provider in the 80th percentile of 715 critical care medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 428 | $321,094 |
| OpsumitMacitentan | 19 | $244,213 |
| OfevNintedanib Esylate | 15 | $213,878 |
| AdempasRiociguat | 12 | $169,331 |
| NucalaMepolizumab | 14 | $154,931 |
| Ambrisentan | 16 | $76,169 |
| Dupixent PenDupilumab | 12 | $45,560 |
| Spiriva RespimatTiotropium Bromide | 53 | $39,542 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 59 | $30,619 |
| Tadalafil | 25 | $27,947 |
| Breo ElliptaFluticasone/Vilanterol | 36 | $20,410 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $15,398 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $11,605 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $10,013 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 272 | $9,272 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $918 | $515,055520 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $77 | $295,643143 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $94 | $244,21319 claims |
| AstraZenecaBreztri Aerosphere | $767 | $10,01314 claims |
| MerckDulera | $146 | $5,57814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Santa Maria
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Cedric Franklin RutlandRiverside$3.2M
- Alex HakimLos Angeles$946K
- Praveen AkuthotaSan Diego$841K
- Wael El MaraachliSan Diego$751K
- Stephen RuossStanford$635K
- Bryon QuickOakland$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.